AVXL

Anavex Life Sciences Corp. NMS · AVXL

$2.52 -0.03 (-1.37%)

Neutral · -0.17σ

+ Compare Open in Sniper

Mkt cap $0.2B

P/E —

Day $2.46 – $2.56

52wk $2.26 – $5.32

Avg vol 1.2M

Beta 1.14

Div yld —

Next earnings 2026-07-23

Quick read

At a glance

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

AVXL last traded at $2.52, down 1.4% on the day; that's in the lower part of its 52-week range ($2.26–$5.32). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-07-23) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — not meaningfully overheated yet.

Long —

Setup score 9 / 100

Price is sitting close to its normal range — no real dip to buy yet.

Technical read: above KC1 lower, -0.13 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 9 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 9 pts

Cycle position 6

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 12 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Aligned with weak downtrend

Technical read: below KC1 upper, -0.13 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 12 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Unknown Accounting: Adequate

Accounting quality Adequate

✓ More cash than debt
✓ Quick ratio 14.82 (antifragile)
✓ Current ratio 11.60 (antifragile)
✓ Debt/equity 0.09 (antifragile)

⚠ Negative retained earnings

Key statistics

All statistics →

AVXL is a $233 million company, the stock is trading near the bottom of its 52-week range.

Market cap $0.2B

P/E ttm —

Beta 1.14

52w range $2.26 – $5.32

Avg volume 1.2M

Dividend yield —

Sector Healthcare

Next earnings 2026-07-23

52-week range · today's price

$2.26$5.32

More on AVXL

Options idea

See more →

CALL $3 2026-08-21

$0.12

PUT $3 2026-08-21

$0.81

Earnings

See more →

Last reported: 2026-02-09
EPS (act / est): -0.06 / -0.11
Surprise: +45.5%
Next report: 2026-07-23

About

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-7…